K., Mathur, A
Reported Limitations and Considerations in GHK-Cu Research Gaps in the Current Evidence Base Despite a substantial pre-clinical record, GHK-Cu lacks large-scale human clinical trial data for most reported applications
Resolution of steatohepatitis and fibrosis reduction occurred in 32.7% of semaglutide-treated patients versus 16.1% in the placebo group (estimated difference 16.5 percentage points, 95% CI 10.222.8)
10.3389/fphys.2020.00694 153 ShenZ.YeC.McCainK.GreenbergM
William Seeds protocol From the peptide reference text "Peptide Protocols, Volume 1": Dose: 100mcg subcutaneously Timing: Approximately 3 hours before bedtime Frequency: Can be done daily, every 3 days, or weekly depending on response This flexible approach allows individualization based on how you respond
Gao S, Yu L, Zhang J, Li X, Zhou J, Zeng P, et al